Individualized brain cell grafts reverse Parkinson’s symptoms in monkeys – University of Wisconsin-Madison

Grafting neurons grown from monkeys own cells into their brains relieved the debilitating movement and depression symptoms associated with Parkinsons disease, researchers at the University of WisconsinMadison reported today.

In a study published in the journal Nature Medicine, the UW team describes its success with neurons made from induced pluripotent stem cells from the monkeys own bodies. This approach avoided complications with the primates immune systems and takes an important step toward a treatment for millions of human Parkinsons patients.

This result in primates is extremely powerful, particularly for translating our discoveries to the clinic, says UWMadison neuroscientist Su-Chun Zhang, whose Waisman Center lab grew the brain cells.

Parkinsons disease damages neurons in the brain that produce dopamine, a brain chemical that transmits signals between nerve cells. The disrupted signals make it progressively harder to coordinate muscles for even simple movements and cause rigidity, slowness and tremors that are the diseases hallmark symptoms. Patients especially those in earlier stages of Parkinsons are typically treated with drugs like L-DOPA to increase dopamine production.

Su-Chun Zhang

Marina Emborg

Those drugs work well for many patients, but the effect doesnt last, says Marina Emborg, a Parkinsons researcher at UWMadisons Wisconsin National Primate Research Center. Eventually, as the disease progresses and their motor symptoms get worse, they are back to not having enough dopamine, and side effects of the drugs appear.

Scientists have tried with some success to treat later-stage Parkinsons in patients by implanting cells from fetal tissue, but research and outcomes were limited by the availability of useful cells and interference from patients immune systems. Zhangs lab has spent years learning how to dial donor cells from a patient back into a stem cell state, in which they have the power to grow into nearly any kind of cell in the body, and then redirect that development to create neurons.

The idea is very simple, Zhang says. When you have stem cells, you can generate the right type of target cells in a consistent manner. And when they come from the individual you want to graft them into, the body recognizes and welcomes them as their own.

The application was less simple. More than a decade in the works, the new study began in earnest with a dozen rhesus monkeys several years ago. A neurotoxin was administered a common practice for inducing Parkinsons-like damage for research and Emborgs lab evaluated the monkeys monthly to assess the progression of symptoms.

We evaluated through observation and clinical tests how the animals walk, how they grab pieces of food, how they interact with people and also with PET imaging we measured dopamine production, Emborg says. (PET is positron emission tomography, a type of medical imaging.) We wanted symptoms that resemble a mature stage of the disease.

The neuron-grafting approach in monkeys takes an important step toward a treatment for millions of human Parkinsons patients.

Guided by real-time MRI that can be used during procedures and was developed at UWMadison by biomedical engineer Walter Block during the course of the Parkinsons study, the researchers injected millions of dopamine-producing neurons and supporting cells into each monkeys brain in an area called the striatum, which is depleted of dopamine as a consequence of the ravaging effects of Parkinsons in neurons.

Half the monkeys received a graft made from their own induced pluripotent stem cells (called an autologous transplant). Half received cells from other monkeys (an allogenic transplant). And that made all the difference.

Within six months, the monkeys that got grafts of their own cells were making significant improvements. Within a year, their dopamine levels had doubled and tripled.

The autologous animals started to move more, Emborg says. Where before they needed to grab the cage to stand up, they started moving much more fluidly and grabbing food much faster and easier.

The monkeys who received allogenic cells showed no such lasting boost in dopamine or improvement in muscle strength or control, and the physical differences in the brains were stark. The axons the extensions of nerve cells that reach out to carry electrical impulses to other cells of the autologous grafts were long and intermingled with the surrounding tissue.

They could grow freely and extend far out within the striatum, says Yunlong Tao, a scientist in Zhangs lab and first author of the study. In the allogenic monkeys, where the grafts are treated as foreign cells by the immune system, they are attacked to stop the spread of the axons.

The results are promising enough that Zhang hopes to begin work on applications for human patients soon.

The missing connections leave the allogenic graft walled off from the rest of the brain, denying them opportunities to renew contacts with systems beyond muscle management.

Although Parkinsons is typically classified as a movement disorder, anxiety and depression are typical, too, Emborg says. In the autologous animals, we saw extension of axons from the graft into areas that have to do with whats called the emotional brain.

Symptoms that resemble depression and anxiety pacing, disinterest in others and even in favorite treats abated after the autologous grafts grew in. The allogenic monkeys symptoms remained unchanged or worsened.

The results are promising enough that Zhang hopes to begin work on applications for human patients soon. In particular, Zhang says, the work Tao did in the new study to help measure the relationship between symptom improvement, graft size and resulting dopamine production gives the researchers a predictive tool for developing effective human grafts.

This research was supported by grants from the National Institutes of Health (NS076352, NS096282, NS086604, U54 HD090256 and P51OD011106), the National Medical Research Council of Singapore, the Dr. Ralph & Marian Falk Medical Research Trust and UWMadison.

Read the original post:

Individualized brain cell grafts reverse Parkinson's symptoms in monkeys - University of Wisconsin-Madison

Read more
New Controversy for Stem Cell Therapy That Repairs Spinal Cords – The Great Courses Daily News

By Jonny Lupsha, Current Events WriterAn alternative to using human embryonic stem cells is to use pluripotent stem cells, which refers to the ability of a stem cell, such as skin cells from an adult, to give rise to other differentiated cell types. Photo By Yurchanka Siarhei / Shutterstock

Patients who have received treatment from their own stem cells to repair their spinal cords are at the center of controversy after the stem cell therapy was fast-tracked in Japan in 2018. Despite 13 patients showing considerable recovery in response to the treatment, the means to this end have suggested improper shortcuts taken in the last several years.

It isnt the first time that stem cell research has been in the spotlight for ethical reasons. One controversial method of obtaining stem cells is to take them from human embryos, which has been argued about for decades. However, alternatives to embryo use are coming to pass.

In his video series Biochemistry and Molecular Biology: How Life Works, Dr. Kevin Ahern, Professor of Biochemistry and Biophysics at Oregon State University, said much about stem cells and the science that surrounds them.

There are two things that are special about stem cells, Dr. Ahern said. One is that they are capable of dividing indefinitelythat is, as long as the organism is alive. The other is that they are undifferentiatedtheyre like a child who hasnt yet chosen whether to be an astronaut, ballerina, surgeon, or an artist.

Dr. Ahern said that when stem cells divide, they can either differentiate and become a specialized cell or they can go back into the stock of stem cells. In an embryo, at the earliest stages of development, the fertilized egg divides to produce a certain number of unspecialized cells called embryonic stem cells. They become specialized by receiving certain signals, so scientists can learn what these signals are and send them to unspecialized cells to make them develop as they wish. This could mean making them become cells to repair nerve damage, heart muscles, and more.

However, some see this as tampering with nature and/or stealing cells from the embryo. Regardless of our opinions one way or the other, these ethical concerns have been raised, prompting scientists to find alternatives.

How else can stem cells be obtained, if not from embryos?

One solution is the production of what are called induced pluripotent stem cells, or iPS cells, Dr. Ahern said. Pluripotent refers to the ability of a stem cell to give rise to other differentiated cell types. To do this and yet avoid working with cells from a human embryo, scientists begin with differentiated somatic cells [like] cells from the skin of an adult, for example.

Once theyve isolated the differentiated somatic cells, scientists reverse engineer them into a state in which they can become any number of differentiated cells or tissues. Dr. Ahern said that iPS cells have been used to create beating heart cells, motor neurons, light-sensing photoreceptor cells, insulin-producing pancreatic cells, and more.

In 2017, Japanese researchers reported that monkeys with Parkinsons showed great improvement after treatment with dopamine-producing neurons derived from iPS cells, Dr. Ahern said. In 2018, clinical trials with humans were begun using iPS cells to treat Parkinsons, heart disease, and macular degeneration.

For now, stem cell therapy remains no stranger to controversyor results. The debate raging around them will likely continue in one way or another for some time.

Edited by Angela Shoemaker, The Great Courses Daily

See more here:

New Controversy for Stem Cell Therapy That Repairs Spinal Cords - The Great Courses Daily News

Read more
Cell Therapy Company Raises $160 Million to Advance iPSC-Derived Therapies to Clinic – BioSpace

Century Therapeuticsreceived a $160 million infusion of cash to advance the companys pipeline of induced pluripotent stem cell (iPSC)-derived cell therapies for cancer.

This morning, the Philadelphia-based company announced a Series C financing round that will drive its preclinical pipeline, which includes multiple iPSC-derived CAR-iT and CAR-iNK cell products, into the clinic over the next 12 months. The companys assets are designed to resist host rejection, enhance cell persistence, and allow repeat dosing to provide durable responses in all patients. Century Therapeutics, which launched in 2019, anticipates clinical testing to begin in 2022 and also predicts it will generate multiple Investigational New Drug applications over the next several years.

The companysgenetically engineered, iPSC-derived iNK and iT cell products are designed to specifically target hematologic and solid tumor cancers. Centurys iPSCs, which are stem cells that can be generated from adult stem cells, have unlimited self-renewing capacity, which enables multiple rounds of cellular engineering. According to the company, these engineering rounds will produce master cell banks of modified cells that can be expanded and differentiated into immune effector cells to supply vast amounts of allogeneic and homogeneous therapeutic products. This platform differentiates Century from competitors that are developing cell therapies made from non-renewable donor-derived cells.

The Series C financing round was led by Casdin Capital and include a number of new investors, including Fidelity Management & Research LLC, the Federated HermesKauffmannFunds, RA Capital, Logos Capital, OrbiMed,Marshall Wace, Qatar Investment Authority, Avidity Partners, and Octagon Capital.Founding investorsVersant Ventures and Leaps by Bayer also participated in the latest fundraising.

We are fortunate to be surrounded by such a top-tier group of investors, whose support will enable the acceleration of Century's technology platform into the clinic, Lalo Flores, chief executive officer of Century Therapeutics said in a statement. With this new investor partnership, we are well-positioned to capitalize on the tremendous potential of our integrated iPSC, cell engineering and manufacturing capabilities to develop safer, more effective and more affordable next generation allogeneic cancer therapies.

Eli Casdin, chief investment of Casdin Capital, who joined the Century Therapeutics Board of Directors following this Series C, said he was excited to partner with the cell therapy company.

It's a remarkable and transformative time in the field, with the ability to engineer cells for therapeutic impact now a commercial reality. At the same time, iPSC technology has matured and is now leading the transition from bespoke autologous products to off-the-shelf allogeneic ones, Casdin said in a statement.

For Century Therapeutics, the financing round was announced about one month after the company expanded its capabilities with new laboratory manufacturing facilities in Pennsylvania and New Jersey. In addition to thePennsylvaniaandNew Jerseylocations, Century has a laboratory inHamilton, Ontariospecifically focused on targeting glioblastoma, and recently opened aSeattle-based innovation hub to help advance the company's novel iPSC platform and support the continued pipeline growth and development.

Last year, Century Therapeutics acquired Empirica Therapeutics to leverage its iPSC-derived allogeneic cell therapies against glioblastoma, one of the most common types of primary brain tumor in adults.

Most Read Today

See the original post here:

Cell Therapy Company Raises $160 Million to Advance iPSC-Derived Therapies to Clinic - BioSpace

Read more
NSAIDs to Treat Arthritic Canines Through 2028; Stem Cell Therapies to Invigorate Canine Arthritis T –

Theglobal Canine Arthritis Treatment Marketis expected to reachUS$ 3051.8 Mnby 2028, growing at a moderate CAGR of 4.4%, as per a market intelligence outlook by Future Market Insights, a premier market research firm delivering actionable insights to key leaders across the globe. Mostly found in ageing canines, canine arthritis is a degenerative condition that results in joints inflammation and progresses with time if left untreated. The condition further worsens resulting in associated conditions like osteoarthritis, osteophytosis, and loss of cartilage, in response to pain and inflammation. Injuries, obesity, and poor bone development often leads to canine arthritis.

Rising number of chronic diseases in dogs, globally, is the primary factor driving canine arthritis treatment adoption. Additional factors like increasing number of veterinary clinics couple with stem cell transplants and Non-steroidal anti-inflammatory medications (NSAIDs) are likely to push the market for canine arthritis treatment. Non-steroidal anti-inflammatory medications (NSAIDs) segment is expected to made substantial revenue contribution to overall canine arthritis treatment market followed by opioids during forecast period.

North America, followed byEuropeandAsia Pacific, is expected to be largest consumer of canine arthritis treatment drugs and therapies, owing to existence of developed regulations and superior healthcare infrastructure. For more collaborative research in the canine arthritis market,JapanandSpainare projected to be promising markets.

A sample of this report is available upon request @

Use of NSAIDs to Further Shape Canine Arthritis Market

Ease of FDA approval for novel and innovative canine arthritis treatment drugs coupled with growing adoption of canine stem therapy to treat arthritis and huge investments in research and development for the production of NSAIDs and opioids indicated for arthritis especially in European countries is projected to projected to present opportunities to canine arthritis treatment product manufacturers.

The focus presently is on developing high grade NSAIDs, as these drugs are frequently used to manage canines condition-offering a dramatic improvement in mobility and quality of life. The demand for NSAIDs in on a perpetual rise as it lowers the production of prostaglandins-associated with driving inflammation leading to arthritis. In terms of treatment, NSAIDs are continue to be the globally accepted mainstay of pharmaceutical treatment for canine arthritis, further shaping the canine arthritis treatment market. Research suggests that more than 60% of canines above the age of 7, suffer from degenerative joint diseases.

According to a Healthcare Expert at Future Market Insights, Factors such as growing prevalence of chronic diseases in dogs, rising pets adoption, increased consumer spending on veterinary care and fast FDA approvals for drugs used for canine arthritis treatments are expected to boost the global canine arthritis treatment market during the forecast period. Additionally, canine owners opting for canine stem cell therapy over drug medicines is the most lucrative segment in terms of investment opportunities. However, safety issues affecting clinical efficacy of canine pluripotent cells and high therapy costs limit the adoption of canine stem cell therapy. FDA-approved MediVets Autologous Stem Cell and Aratanas Galliprant to control pain and inflammation associated with arthritis, are expected to contribute to the growth of the canine arthritis treatment market.

However, illicit drugs that are falsely registered could restrain the canine treatment market. Such drugs are not manufactured in accordance with regulations, inversely affecting the dogs health coupled with sales of approved drugs. Research shows that counterfeit medicines are more prevalent in under-developed and developing countries. Growing international trade and ecommerce penetrations are fuelling the sales of sub-standard medicine.

Get Access to Research Methodology Prepared by Experts>>>

Canine Insurances & Direct Drug Sales to Open Canine Arthritis Treatment Opportunities

Pet insurance is an upcoming trend, especially in mature economies. With only 1% dogs insured in the US, the trend is catching up in the region, opening up opportunities for veterinary insurance vendors. However, this number is as high as 50% for pet dogs in some European countries. Moreover, introduction of third-party payers is expected to boost the turnover of the canine arthritis drugs, mostly for the NSAIDs and stem cell therapy segments globally, and lead to build-up of new sales channels for drugs treating canine arthritis.

Also, canine healthcare products manufacturers are relying on direct sales to end-users in a bid to reach out to a larger consumer base. Furthermore, by adopting this sales route, companies are also providing additional training and support in terms of disease management and adherence to treatment protocols.

Key players including Boehringer Ingelheim, Elanco (Eli Lilly and Company), Zoetis Inc., Bayer AG, Aratana Therapeutics Inc., Vetoquinol S.A., Norbrook Laboratories Limited, VetStem Biopharma, and Dechra Pharmaceuticals Plc are developing cost-effective drugs for canine arthritis treatment and increasing sales through acquisitions to enhance their respective market share. Manufacturers are also focusing in developing novel stem cell therapies for treating arthritis. Moreover, companies are focusing partnering with wholesalers, distributors and other channel partners to gain ownership over value chain.

Preview Analysis OnCanine Arthritis Treatment Market Segmentation By treatment type Non-steroidal anti-inflammatory drugs, Opioids, Stem Cell Therapy; route of administration Oral, Injectable:

More from Healthcare, Pharmaceuticals and Medical devices:

Read this article:

NSAIDs to Treat Arthritic Canines Through 2028; Stem Cell Therapies to Invigorate Canine Arthritis T -

Read more
A region within GLI1 gene could potentially be targeted as cancer treatment – News-Medical.Net

Scientists from the Stanley Manne Children's Research Institute at Ann & Robert H. Lurie Children's Hospital of Chicago found that a region within the DNA of the cancer-promoting GLI1 gene is directly responsible for regulating this gene's expression. These findings, published in the journal Stem Cells, imply that this region within GLI1 could potentially be targeted as cancer treatment, since turning off GLI1 would interrupt excessive cell division characteristic of cancer.

From previous research, we know that GLI1 drives the unrelenting cell proliferation that is responsible for many cancers, and that this gene also stimulates its own expression. We established in living human embryonic stem cells that removing the GLI1 regulatory region eliminated GLI1 expression and halted its activity. These findings are promising and could point to a therapeutic target for cancer."

Philip Iannaccone, MD, PhD, Co-Senior Author, Professor Emeritus at the Manne Research Institute, Lurie Children's and Northwestern University Feinberg School of Medicine

Dr. Iannaccone and colleagues used CRISPR gene editing technology to delete the binding region of the GLI1 DNA in human embryonic stem cells. They found that without this region, GLI1 remained turned off, which interfered with the gene's normal activity of driving embryonic development of blood, bone, and nerve cells.

"A surprising aspect of this work was that turning GLI1 off affected stem cell differentiation to all three embryonic lineages," says first author Yekaterina Galat, BS, Research Associate at the Manne Research Institute at Lurie Children's.

"The developmental function of GLI1 ends after birth, so if we manage to stop its expression in the context of cancer, it should not have negative consequences to normal biology," explains Dr. Iannaccone.

GLI1 expression is associated with about a third of all human cancers. In addition to promoting cell proliferation, GLI1 expression increases tumor cell migration and is associated with resistance to chemotherapy drugs.

"Our team plans to study GLI1 associated proteins that assist in regulation of GLI1 expression through its binding region," says Dr. Iannaccone. "Targeting these proteins as a means to stop GLI1 activity could prove to be a fruitful treatment strategy for cancer."

Continue reading here:

A region within GLI1 gene could potentially be targeted as cancer treatment - News-Medical.Net

Read more
Magenta Therapeutics Reports Fourth Quarter and Full-Year 2020 Financial Results and Recent Program Highlights – Galveston County Daily News

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 3, 2021--

Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today reported financial results for the fourth quarter and full-year ended December 31, 2020 and recent program highlights.

Building on our momentum from 2020, we continue to advance our portfolio with now two active Phase 2 clinical trials evaluating MGTA-145 plus plerixafor in patients with blood cancers undergoing autologous and allogeneic stem cell transplant and an additional planned Phase 2 clinical trial evaluating stem cell mobilization and collection in patients with sickle cell disease in partnership with bluebird bio. We have also made additional progress in our preparations for an IND filing for our MGTA-117 targeted conditioning program based on communications with the FDA and the advancement of our IND-enabling studies, said Jason Gardner, D.Phil., President and Chief Executive Officer, Magenta Therapeutics. We very much look forward to generating clinical data during the course of 2021 in these multiple disease settings.

Program Highlights:

MGTA-145: Stem Cell Mobilization and Collection for Hematopoietic Stem Cell Transplantation and Gene Therapy

Magenta is developing MGTA-145 plus plerixafor to harness these agents complementary mechanisms to mobilize hematopoietic stem cells (HSCs) for collection and transplantation, including for use with gene therapies. The ability to provide rapid, reliable, predictable and safe mobilization and collection of HSCs in stem cell transplantation and gene therapy could position MGTA-145 plus plerixafor to be the preferred mobilization regimen across multiple diseases due to improved patient experience and collection outcomes.

MGTA-145 Current and Planned Activity:

MGTA-145 Recent and Upcoming Scientific Conference Presentations:

MGTA-117: Targeted Conditioning

Magenta is developing a platform of novel antibody-drug conjugates (ADCs) for conditioning, a step in the transplant process that currently relies on the use of systemic chemotherapy agents and radiation. Magentas targeted conditioning programs are designed to selectively eliminate stem cells and/or immune cells from a patient prior to transplant or gene therapy, and to reduce or potentially eliminate the need for high dose or high intensity chemotherapy-based regimens.

MGTA-117, Magentas most advanced conditioning program, is a CD117-targeted antibody conjugated to amanitin and intended for use in patients undergoing transplant. MGTA-117 is designed to deplete hematopoietic stem and progenitor cells to clear space in the bone marrow prior to transplant in support of long-term engraftment and improved disease outcomes in patients. MGTA-117 has shown high selectivity, potent efficacy and tolerability in multiple preclinical studies.

Targeted Conditioning Current and Planned Activity:

Targeted Conditioning Recent and Upcoming Scientific Conference Presentations:

Financial Results:

Cash Position: Cash, cash equivalents and marketable securities as of December 31, 2020, were $148.8 million, compared to $145.7 million as of December 31, 2019. Magenta anticipates that its cash, cash equivalents and marketable securities will be sufficient to fund operations and capital expenditures into 2023.

Research and Development Expenses: Research and development expenses were $12.3 million in the fourth quarter of 2020, compared to $18.7 million in the fourth quarter of 2019. The decrease was driven primarily by decreased preclinical costs for manufacturing related to the conditioning programs, lower manufacturing and clinical trial costs due to the discontinuance of enrollment in the Phase 2 clinical trial of MGTA-456 in inherited metabolic diseases in June 2020 and lower clinical trial costs for the MGTA-145 Phase 1 clinical trial which was completed in the first quarter of 2020.

General and Administrative Expenses: General and administrative expenses were $6.8 million for the fourth quarter of 2020, compared to $5.9 million for the fourth quarter of 2019. The increase was primarily due to an increase in personnel costs, professional services and insurance costs associated with Magentas expanded clinical trial preparations.

Net Loss: Net loss was $18.2 million for the fourth quarter of 2020, compared to net loss of $23.2 million for the fourth quarter of 2019.

About Magenta Therapeutics

Magenta Therapeutics is a clinical-stage biotechnology company developing medicines to bring the curative power of immune system reset through stem cell transplant to more patients with blood cancers, genetic diseases and autoimmune diseases. Magenta is combining leadership in stem cell biology and biotherapeutics development with clinical and regulatory expertise, a unique business model and broad networks in the stem cell transplant community to revolutionize immune reset for more patients.

Magenta is based in Cambridge, Mass. For more information, please visit

Follow Magenta on Twitter: @magentatx.

Forward-Looking Statement

This press release may contain forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws, including express or implied statements regarding Magentas future expectations, plans and prospects, including, without limitation, statements regarding expectations and plans for presenting pre-clinical and clinical data, projections regarding future revenues and financing performance, our long-term growth, cash, cash equivalents and marketable securities, the anticipated timing of our clinical trials and regulatory filings, the development of our product candidates and advancement of our preclinical programs, the timing, progress and success of our collaborations, as well as other statements containing the words anticipate, believe, continue, could, endeavor, estimate, expect, anticipate, intend, may, might, plan, potential, predict, project, seek, should, target, will or would and similar expressions that constitute forward-looking statements under the Private Securities Litigation Reform Act of 1995. The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation: uncertainties inherent in clinical studies and in the availability and timing of data from ongoing clinical studies; whether interim results from a clinical trial will be predictive of the final results of the trial; whether results from preclinical studies or earlier clinical studies will be predictive of the results of future trials; the expected timing of submissions for regulatory approval or review by governmental authorities; regulatory approvals to conduct trials or to market products; whether Magenta's cash resources will be sufficient to fund Magenta's foreseeable and unforeseeable operating expenses and capital expenditure requirements; risks, uncertainties and assumptions regarding the impact of the continuing COVID-19 pandemic on Magentas business, operations, strategy, goals and anticipated timelines, Magentas ongoing and planned preclinical activities, Magentas ability to initiate, enroll, conduct or complete ongoing and planned clinical trials, Magentas timelines for regulatory submissions and Magentas financial position; and other risks concerning Magenta's programs and operations are described in additional detail in its Annual Report on Form 10-K expected to be filed on or about March 3, 2021, its Quarterly Reports on Form 10-Q and its other filings made with the Securities and Exchange Commission from time to time. Although Magenta's forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Magenta. As a result, you are cautioned not to rely on these forward-looking statements. Any forward-looking statement made in this press release speaks only as of the date on which it is made. Magenta undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.






























Visit link:

Magenta Therapeutics Reports Fourth Quarter and Full-Year 2020 Financial Results and Recent Program Highlights - Galveston County Daily News

Read more
Global Animal Stem Cell Therapy Market 2020 2025 Research Report Segment Outlook, Growth Potentials and Analysis of COVID-19 Worldwide Outbreak KSU… has presented updated research report titled Global Animal Stem Cell Therapy Market 2020 by Manufacturers, Type and Application, Forecast to 2025 which presents vital answers and interpretations concerning market growth and developments in the market. The report contains insightful information like market share, market size, and growth rate, as well as several challenges and ingrained threats and limitations that have interrupted normal growth prognosis in global Animal Stem Cell Therapy market. The report analyzes the segment expected to dominate the industry and market.This market report includes quantitative and qualitative estimation by industry experts, the contribution from industry across the value chain. The report gives information about the supply and demand situation, the competitive scenario, market opportunities, and the threats faced by key players.

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

Competitive Intelligence:

The leading players are covered in the global Animal Stem Cell Therapy market report with product description, business outline, as well as production, future demand, company profile, product portfolio, product/service price, capacity, sales, and cost. So the entire information related to the company concerning the specific product and in-depth information of collaborations and all other essential information is added in the research report.


Report has been segmented into geographical segmentation, key players, key topics industry value and demand analysis and forecast and gives comprehensive investigation.The report provides knowledge of the key product segments and their future by having complete insights of market and by making in-depth analysis of market segments. Report includes supply-demand statistics, and segments that constrain the growth of an industry. It also includes raw materials used and manufacturing process of global Animal Stem Cell Therapy market.

All top players actively involved in this industry are as follows: Medivet Biologics LLC, Kintaro Cells Power, U.S. Stem Cell, Inc, VETSTEM BIOPHARMA, Magellan Stem Cells, J-ARM, Animal Cell Therapies, Celavet Inc., VetCell Therapeutics, Animal Stem Care, Cell Therapy Sciences, Animacel

The report highlights product types which are as follows:Dogs, Horses, Others

The report highlights top applications which are as follows:Veterinary Hospitals, Research Organizations

Promising regions & countries mentioned in the global Animal Stem Cell Therapy market report:North America (United States, Canada and Mexico), Europe (Germany, France, United Kingdom, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), South America (Brazil, Argentina), Middle East & Africa (Saudi Arabia, UAE, Egypt and South Africa)

Market By Manufacturing Cost Analysis:

The study report includes key raw materials analysis, the price trend of key raw materials, key suppliers of raw materials, market concentration rate of raw materials, the proportion of manufacturing cost structure, and manufacturing process analysis. Moreover, the report evaluates the product pricing, production capacity, demand, supply, as well as the historical performance of the global Animal Stem Cell Therapy market.


Report Offerings:

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: [emailprotected]Web:

Originally posted here:

Global Animal Stem Cell Therapy Market 2020 2025 Research Report Segment Outlook, Growth Potentials and Analysis of COVID-19 Worldwide Outbreak KSU...

Read more
Global Autologous stem cell and Non-stem cell based Therapies Market- Industry Analysis, Growth, Segmentation and Forecast-2019-2027 – The Bisouv…

Maximize Market Research has recently published a Global Autologous stem cell and Non-stem cell based Therapies Market 2019 Industry Research Report. It is comprehensive analysis of past and current status Autologous stem cell and Non-stem cell based Therapies Marketwith the forecast till 2027. The report covers the past market from 2017 to 2019 and forecast of 2020 to 2027 with key developments, key trends, M&A activities by value and their strategic intents. The report has analysed complex data and presented in simple format to make it easlier to understand.

The Market structure presented in the report gives detailed analysis of market leaders, followers and new entrants by region. Glance at couple of slides will give an idea about the market structure with the market share commanded by leaders, followers and unconsolidated/local but important players.

Request For View Sample Autologous stem cell and Non-stem cell based Therapies Market Report Page :

PORTER, SVOR, PESTEL analysis by region is covered for the companies or individual investors who are looking at specific market for expansion or entry. Micro as well as Macro economic factors are analysed to understand its impact on market growth and key players top lines.The report also helps in comprehending the Autologous stem cell and Non-stem cell based Therapies dynamics, structure by analysing the industry segments and project the Autologous stem cell and Non-stem cell based Therapies Market size. To stand apart, the clear representation of competitive analysis of key market players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Autologous stem cell and Non-stem cell based Therapies Market make the report investors guide.Additionally, the Autologous stem cell and Non-stem cell based Therapies market report 2019 2027, gives the competitive landscape of the global industry by region, key players products and services benchmarking, market domination by segment, pricing and end user penetration, investment in R&D and patents. Couple of slides will give the complete competitive landscape of the industry.

By segments, the market is divided intoMarket segmentation

The ACT and non-ACT therapies market is segmented based on-


Neurodegenerative disorders Autoimmune diseases Cancer and Tumours Cardiovascular Diseases


Blood Pressure monitoring devices Pulmonary pressure monitoring devices Intracranial pressure monitoring devices


Hospitals Ambulatory surgical centers Others

Regional Insights

Global Autologous stem cell and Non-stem cell based Therapies Market1

North America dominates the Autologous Stem cells and Non-Autologous stem cell based therapies market.

North America dominated the stem cell market contributing to the largest share of xx% in the market. The availability of funds from various organizations and presence of key players in the region is encouraging investors to invest more. Various stem cell studies across the US are helping the market to accelerate.In SA and NA, treatments through ACT and non-ACT based therapies for diabetes and other diseases are actively progressing. European countries are also actively engaged in the development of ACT and non-ACT based therapies. In developing nations of the APAC region large investments are being made for stem cell therapies, which is expected to drive the market growth.Key Players operating the Global Autologous stem cell and non-autologous stem cell market

Fibrocell Science, Inc Astrom Biosciences Dendreon Corporation NeoStem, Inc Brainstorm Cell therapeutics Regeneus Ltd Genzyme Corporation Antria Bioheart Cytori Therapeutics Genesis Biopharma Opexa Therapeutics Orgenesis Regenexx Tengion Sanofi Mesoblast Ltd Virxsys StemGeneXamong Vericel Corporation Med Cell Europe AG IovanceBiotherapeutics Inc

SWOT analysis of player will give a detailed strategic input about the key players in industry by region. Experienced research analysts in the field are following the key players that are profiled in the Autologous stem cell and Non-stem cell based Therapies report that are considered while estimating the market size. Research analyst working in the field for more than ten years, give them advantage to follow same market for years and have become seasoned consultants in the Autologous stem cell and Non-stem cell based Therapies industry.

Do Inquiry Before Purchasing Market Autologous stem cell and Non-stem cell based Therapies Report Here :

Table of Contents

Browse Complete Autologous stem cell and Non-stem cell based Therapies Report details with ToC and List Of Figures Here:

About Us:Maximize Market Research has served esteemed clients including Yamaha, Boeing, Sensata, Etnyre, Canada, ALCOR M&A, Microsoft, Harman, and other 200 MNCs worldwide. The Company provides B2B and B2C market research on 5000 high growth emerging technologies & opportunities in Transportation, Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.We, at Maximize Market Research, are a strong unified team of industry specialists and analysts across sectors to ensure entire Industry ecosystem is taken in perspective, factoring all recent development, latest trends and futuristic the technological impact of uniquely specific industries. In line with the agreed scope and objective of the study, our approach is uniquely custom detailed

Contact Us:Maximize Market Research Pvt ltdPhone: +91 9607195908 / +1 7747752163Email: [emailprotected]


Read the original post:

Global Autologous stem cell and Non-stem cell based Therapies Market- Industry Analysis, Growth, Segmentation and Forecast-2019-2027 - The Bisouv...

Read more
Stem Cell manufacturing Market Witness an Outstanding Growth and Strong Revenue and Forecast 2027 KSU | The Sentinel Newspaper – KSU | The Sentinel…

The latest Reportrelease from Database of Data Bridge Market Research has recently published the research Report TitledStem Cell manufacturing Market. The study provides an overview of current statistics and future predictions of the Global Stem Cell manufacturing Market.The study highlights a detailed assessment of the Market and displays market sizing trends by revenue & volume (if applicable), current growth factors, expert opinions, facts, and industry-validated market development data.

Stem Cell manufacturing Market Insight:

Stem cell manufacturing market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account to USD 18.59 billion by 2027 growing at a CAGR of 6.42% in the above-mentioned forecast period. The growing awareness towards diseases like cancer, hematopoietic disorders and degenerative disorders is going to drive the growth of the stem cell manufacturing market.

Download Free Exclusive Sample (350 Pages PDF) Report: To Know the Impact of COVID-19 on Stem Cell manufacturing Market[emailprotected]

Prominent Key Players Covered in the report:

Thermo Fisher Scientific., Merck KGaA, BD, JCR Pharmaceuticals Co., Ltd., Organogenesis Inc, Osiris, Vericel Corporation, AbbVie Inc., AM-Pharma B.V., ANTEROGEN.CO.,LTD., Astellas Pharma Inc., Bristol-Myers Squibb Company, FUJIFILM Cellular Dynamics, Inc., RHEACELL GmbH & Co. KG, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., ViaCyte,Inc., VistaGen Therapeutics Inc, GlaxoSmithKline plc, DAIICHI SANKYO COMPANY, LIMITED (Customization Available)

The GlobalStem Cell manufacturing Marketresearch report assembles data collected from different regulatory organizations to assess the growth of the segments. In addition, the study also appraises the global Stem Cell manufacturing market on the basis of topography. It reviews the macro- and microeconomic features influencing the growth of the Stem Cell manufacturing Market in each region. Various methodological tools are used to analyze the growth of the worldwide Stem Cell manufacturing market.

Major Regions as Follows:

Global Stem Cell manufacturing Market Research Reportalso provides the latest companies data and industry future trends, allowing you to identify the products and end users driving profits growth and productivity. The Market report lists the most important competitors and provides the insights strategic industry Analysis of the key factors influencing the market. The report includes the forecasts, investigation and discussion of significant industry trends, market volume, market share estimates and profiles of the leading industry Players. Global Stem Cell manufacturing Industry Market Research Report is providing exclusive vital statistics, information, data, trends and competitive landscape details. The Global Stem Cell manufacturing market SWOT is provided for the international markets including progress trends, competitive landscape breakdown, and key in regions development status.

Get Table Of Contents of This Premium Research For Free:

How Does This Market Insights Help?

Key Pointers Covered in the Stem Cell manufacturing Market Industry Trends and Forecast

Why choose us:

Market Dynamics:The Stem Cell manufacturing report also demonstrates the scope of the various commercial possibilities over the coming years and the positive revenue forecasts in the years ahead. It also studies the key markets and mentions the various regions i.e. the geographical spread of the industry.

Strategic Points Covered in Table of Content of Global Stem Cell manufacturing Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the Stem Cell manufacturing market

Chapter 2: Exclusive Summary the basic information about the Stem Cell manufacturing Market.

Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges of the Stem Cell manufacturing

Chapter 4: Presenting the Stem Cell manufacturing Market Factor Analysis Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.

Chapter 5: Displaying market size by Type, End-User and Region 2010-2019

Chapter 6: Evaluating the leading manufacturers of the Stem Cell manufacturing market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile

Chapter 7: To evaluate the market by segments, by countries and by manufacturers with revenue share and sales by key countries.

Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

Finally, Stem Cell manufacturing Market is a valuable source of guidance for individuals and companies in the decision framework.

Stem Cell manufacturing Marketwill prove as a valuable source of guidance for professional clients like Tier 1, Tier 2, Tier 3 level managers, CEOs, CMOs, as well as the interested individual readers across the world. Vendor Landscape provide acts as key development and focus of above professional with common aim to lead the way of Stem Cell manufacturing Market Worldwide

In Conclusion:

The Stem Cell manufacturing Market report is a reliable source for accessing the research data that is projected to exponentially accelerate your business. The report provides information such as economic scenarios, benefits, limits, trends, market growth rates, and figures. SWOT analysis is also incorporated in the report along with speculation attainability investigation and venture return investigation.

Get Enquiry About This Comprehensive Report:

Thank you for reading this article. You can also get chapter-wise sections or region-wise report coverage for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Customization of the Report:

We are grateful to you for reading our report. If you wish to find more details of the report or want customization, contact us. You can get a detail of the entire research here. If you have any special requirements, please let us know and we will offer you the report as you want.

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to complex business challenges and initiates an effortless decision-making process.


US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475


Read more:

Stem Cell manufacturing Market Witness an Outstanding Growth and Strong Revenue and Forecast 2027 KSU | The Sentinel Newspaper - KSU | The Sentinel...

Read more
New study launches into COVID-19 vaccine responses in patients with impaired immune systems – University of Birmingham

Researchers will build on years of experience in understanding the immune system in the context of chronic conditions, to better determine the effectiveness of COVID-19 vaccines in certain clinically at-risk patient groups

A new UK study sponsored and run by the University of Birmingham has launched aiming to better understand the immune response to COVID-19 vaccinations in patients with certain immunosuppressed conditions including cancer.

The OCTAVE trial, which is funded by the Medical Research Council (MRC), is a collaborative research project involving the Universities of Birmingham, Glasgow, Oxford, Liverpool, Imperial College London and Leeds Teaching Hospitals NHS Trust. Researchers will build on years of experience in understanding the immune system in the context of chronic conditions, to better determine the effectiveness of COVID-19 vaccines in these clinically at-risk patient groups.

People with cancer, inflammatory arthritis, diseases of the kidney or liver, or who are having a stem cell transplant, may be at increased risk of the more severe complications of COVID-19 infection. As a result, the rollout of vaccines is especially welcome for these vulnerable groups. However, these underlying medical conditions and the treatment that such patients receive as part of their care, may weaken the immune system.

Professor Pam Kearns, Director of the University of Birminghams Cancer Research UK Clinical Trials Unit (CRCTU), which will be running the study, said: Current evidence shows that people with these medical conditions may not obtain optimal protection from established vaccines.

Patients with significant underlying diseases were generally excluded from COVID-19 vaccine studies to date it is now important to confirm that the COVID-19 vaccines work well in such conditions.

We are pleased to be supporting this important nationally collaborative study that will inform the best use of the COVID-19 vaccines to protect these vulnerable patients.

The OCTAVE study will investigate the effectiveness of COVID-19 vaccines being used in the UK in 2021 in up to 5,000 people within these patient populations. Using a variety of state-of-the-art immune tests performed on blood samples taken before and/or after COVID-19 vaccination, researchers will determine patients COVID-19 immune response and, therefore, the likelihood that vaccines will fully protect these groups from SARS-CoV-2 infection.

Researchers have begun recruiting patients at sites across the UK, and will compare results from the study group against control groups of healthy people without underlying diseases who also received COVID-19 vaccines. The OCTAVE study will evaluate patients who receive COVID-19 vaccines as part of the national vaccination programme.

Professor Iain McInnes, Head of the College of Medical, Veterinary and Life Sciences at the University of Glasgow who leads the OCTAVE study, said: We urgently need to understand if patient populations with chronic conditions such as cancer, inflammatory arthritis and kidney and liver disease are likely to be well-protected by current COVID-19 vaccines. The OCTAVE study will give us invaluable new data to help us answer questions of this kind from our patients and their families.

Scientists do not yet know how long COVID-19 vaccines provide immunity for, and there may be an ongoing vaccination requirement against the disease for years to come. This may be especially so in people with weakened immune systems, due to drug treatments and underlying disease. Results from the OCTAVE study will help to inform how best to vaccinate patients with chronic conditions, and protect them from SAAR-CoV-2 infection.

Professor Fiona Watt, Executive Chair of the Medical Research Council, which funded the study, said: This study is investigating the response to the new COVID-19 vaccines in people whose immune systems make them more vulnerable to COVID-19 and other infections. This will help ensure that those more at risk from infection receive the best protection possible.

Notes to Editors


New study launches into COVID-19 vaccine responses in patients with impaired immune systems - University of Birmingham

Read more